RxDoctor Payments Data

Laura Wroge, PA

Physician Assistant · Highland, ILNPI 1972907848

Payments from drug & device makers

$671in general payments, 2019–2025

Across 25 payments — averaging $26.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$322
  • Amgen$65
  • Lilly USA, LLC$54
  • AbbVie$50
  • Valinor Pharma, LLC$49
  • Novo Nordisk$46
  • plus $86 from 4 others

What the payments were for

  • Food & beverage$65497%
  • Other$183%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca5$322
Amgen3$65
Lilly USA, LLC3$54
AbbVie3$50
Valinor Pharma, LLC3$49
Novo Nordisk3$46
Boehringer Ingelheim2$40
Baxter Healthcare1$18
Exact Sciences1$16
GSK1$13

How this compares

$671 in reported general payments places this provider in the 65th percentile of 3,912 physician assistant providers in Illinois.

See all physician assistant providers in Illinois

Medicare billing

Part B allowed, 2024
$1,606
Medicare patients
67
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide47$47,798
EliquisApixaban32$23,411
TrulicityDulaglutide23$21,898
OzempicSemaglutide16$19,562
RybelsusSemaglutide17$17,459
MyrbetriqMirabegron21$14,272
FarxigaDapagliflozin Propanediol13$8,271
Duloxetine Hcl60$1,466
Gabapentin61$1,277
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,087
Omeprazole69$951
Albuterol Sulfate HfaAlbuterol Sulfate32$945
Atorvastatin Calcium121$930
Rosuvastatin Calcium43$855
Levothyroxine Sodium112$844

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$54$69,69670 claims
Novo NordiskOzempic, Rybelsus$46$37,02133 claims
AstraZenecaFarxiga$322$8,27113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,912 physician assistant providers in Illinois.

Other physician assistant in Highland

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →